Study Of The Relationship Between Biomarkers And The Prognosis Of Breast Cancer

Background:MicroRNA-21(miRNA-21or miR-21) may act as a prognostic biomarker of cancer. However, the available evidence is controversial. Therefore, the present meta-analysis summarizes this evidence and evaluates the prognostic role of this gene in breast cancer.Methods:The meta-analysis was conducted by searching the databases of PubMed, EMBASE, Web of Science and Chinese database-China National Knowledge Infrastructure (CNKI). Data were extracted from studies that investigated the association between miR-21expression and survival outcomes in breast cancer patients. With respect to survival outcomes, the pooled hazard ratios (HRs) of miR-21were calculated given a95%confidence interval (CI).Results:Our meta-analysis identified a total of10studies involving1,439cases. Further investigation demonstrated that a high miR-21expression can predict poor overall survival (OS)(HR=2.57,95%CI:1.37-4.81, P=0.003) and shortened disease-free/recurrence-free survival (DFS/RFS)(HR-1.45,95%CI:1.16-1.82,P=0.001) in breast cancer patients. Moreover, high miR-21expression was significantly correlated with lowered OS in the Asian group (HR=5.07,95%CI:2.89-8.92,P<0.001), but not in the Caucasian cohort (HR=1.44,95%CI:0.99-2.10,P=0.058). Furthermore, odds ratios (ORs) showed that up-regulated miR-21levels were associated with multiple clinical characteristics.. Conclusions:Our results indicated that miR-21can predict unfavorable prognoses in breast cancer patients, especially in Asians. Background:To investigate the predictive role of multiple clinicopathological features such as biological markers and molecular subtypes for breast cancer patients’ response to neoadjuvant chemotherapy.Methods:Retrospective analysis was conducted based on medical records of patients who had undergone neoadjuvant chemotherapy for breast cancer between January2013and March2015. Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2(Her-2) and Ki-67index were detected by immunohistochemical assay in core-needle biopsy specimens. Based on ER, PR, Her2and Ki-67status, patients were divided into Luminal A, Luminal B, Her2positive and triple negative phenotype. The relationships between clinicopathological and responses were analyzed by SPSS17.0software.Results:The pathological complete response (pCR) rate was24.42%in a total of86 enrolled patients. The overall clinical response rate was69.77%. In the univariate analysis, absence of ER or PR was predictive of the pCR (P<0.05). The administration of chemotherapy and trastuzumab led to a greater overall response rate compared with chemotherapy alone in Her2positive patients (P=0.021). In the multivariate analysis, pCR rate in triple negative patients was46.2%, which was significant higher than that of other subtypes (P=0.046).Conclusions:Negative hormonal receptor status was more sensitive to neoadjuvant chemotherapy. Her2positive patients who received trastuzumab and chemotherapy had a significantly better response. Triple-negative breast cancer had a higher pCR rate, thus, neoadjuvant treatment should be considered for triple negative breast cancer.